Biology, asked by goutamkumartoi8625, 1 year ago

Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and t-cell lymphoma

Answers

Answered by shivangi4555
0
hey mate mark it as brainlist




that an antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans. Structure-function analyses pointed to a proton at position-9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Thus, many noscapine analogs with different functional moieties at position-9 were synthesized. Those analogs that kill human cancer cells resistant to other antimicrotubule agents, vincas and taxanes, were screened. Here, we present one such analog, 9-nitro-noscapine (9-nitro-nos), which binds tubulin and induces apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine, and teniposide. 9-Nitro-nos treatment at doses as high as 100 microM did not affect the cell cycle profile of normal human fibroblasts. This selectivity of 9-nitro-nos for cancer cells represents a unique edge over the other available antimitotics. 9-Nitro-nos perturbs the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of terminal deoxynucleotidyl transferase dUTP nick-end labeling-positive cells. Thus, we conclude that 9-nitro-nos has great potential to be a novel therapeutic agent for ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.
Answered by TheHoneyBabe
8

Explanation:

A cancer of the lymphatic system.

The lymphatic system is the body's disease-fighting network. It includes the lymph nodes, spleen, thymus gland and bone marrow. The main types of lymphoma are Hodgkin's lymphoma and non-Hodgkin's lymphoma.

Similar questions